SCHEMBL1007078

SCHEMBL1007078

CC(C)(C)OC(=O)NCCn1nc(C(=O)O)c([N+](=O)[O-])c1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
GFER P55789 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 2/20 0.36
BRD4 O60885 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
PKM P14618 1/20 0.34
DRD2 P14416 2/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
PRMT1 Q99873 1/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890830 0.86 ALDH1A1 (0.37) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL27176043 0.81 ALDH1A1 (0.39) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL31616888 0.78 ALDH1A1 (0.35) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL1079551 0.78 GAA (0.50) ALDH1A1GAATDP1LMNAHTT
SCHEMBL5163133 0.77 ALDH1A1 (0.38) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL28092204 0.75 ALDH1A1 (0.40) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL20139539 0.74 ALDH1A1 (0.39) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL16297436 0.73 ALDH1A1 (0.39) ALDH1A1GFERMEN1KMT2AGAA
SCHEMBL330893 0.72 KMT2A (0.38) ALDH1A1MEN1KMT2ACNR1CNR2
SCHEMBL31357676 0.71 BCHE (0.47) MEN1KMT2AGAABRD4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
US-20050107412-A1 Pharmaceutically active compounds PFIZER INC 2005-05-19 US disclosed
US-6831074-B2 Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders PFIZER INC 2004-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107412-A1 Pharmaceutically active compounds PDE5A, PDE2A, PDE3B ALDH1A1 720/4885GFER 3232/4885MEN1 2652/4885
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885GFER 1046/4885MEN1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.